AR and prostate carcinoma: Hormonal therapies frequently fail and patients may relapse with ‘castrate-resistant’ prostate cancer.2, 3, 4 Resistance results from clonal selection of cells that circumvent androgen requirement by mechanisms including AR mutation, amplification or changes in AR cofactor (coactivator and corepressor) levels.